Treatment patterns1 anti-vascular endothelial growth factor and laser therapy among patients with diabetic macular edema

Journal of Managed Care Pharmacy

Volumn 21, Issue 9, 2015, Pages 735-741

  Jiang, Shan ^a,b   Barner, Jamie C ^b   Park, Chanhyun ^b   Ling, You Li ^b  

^a PHARMERIT INTERNATIONAL   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; STEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; APTAMER; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DIABETIC MACULAR EDEMA; FEMALE; HISPANIC; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRESCRIPTION; RETROSPECTIVE STUDY; VISUAL IMPAIRMENT; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG SAFETY; INJECTION; LASER SURGERY; LOGISTIC REGRESSION ANALYSIS; LOW LEVEL LASER THERAPY; PREDICTOR VARIABLE; RISK FACTOR; STEROID THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DIABETIC RETINOPATHY; MACULAR EDEMA; MIDDLE AGED; PATHOLOGY; PROCEDURES; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; APTAMERS, NUCLEOTIDE; BEVACIZUMAB; COHORT STUDIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; LASER THERAPY; LOGISTIC MODELS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84946406306     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653-64.
2. Arevalo JF. Diabetic macular edema: changing treatment paradigms. Curr Opin Ophthalmol. 2014;25(6):502-07.
3. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred practice pattern guidelines: diabetic retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2014. Available at: http://www.aao. org/preferred-practice-pattern/diabetic-retinopathy-ppp--2014. Accessed July 30, 2015.
4. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
5. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophth Vis Sci. 2003;44(7):3186-93. Available at: http://www. iovs.org/content/44/7/3186.long. Accessed July 13, 2015.
6. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
7. National Institute for Health and Clinical Excellence. Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237). April 2013. Available at: https://www.nice.org.uk/guidance/ta274/resources/guidance-ranibizumab-for-treating-diabetic-macular-oedema-rapid-review-of-technology-appraisal-guidance-237-pdf. Accessed July 13, 2015.
8. Shea AM, Curtis LH, Hammill BG, et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol. 2008;126(12):1748-54. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630411//. Accessed July 13, 2015.
9. Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284,380 Medicare beneficiaries. Am J Ophthalmol. 2012;153(6):1116-24.
10. Johnston SS, Wilson K, Huang A, Smith D, Varker H, Turpcu A. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. Adv Ther. 2013;30(12):1111-27. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906738//. Accessed July 13, 2015.
11. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred practice patterns: age-related macular degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at: http://www.aao. org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015. Accessed July 30, 2015
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-19.
14. Chang MA, Fine HF, Bass E, et al. Patients' preferences in choosing therapy for retinal vein occlusions. Retina. 2007;27(6):789-97.
15. Schwartz SG, Flynn HW Jr. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor injections. Curr Ophthalmol Rep. 2014;2(1):1-5.
16. Palmer JM, Amoaku WM, Kamali F. Quality of bevacizumab compounded for intravitreal administration. Eye (Lond). 2013;27(9):1090-97.
17. Schmucker C, Loke YK, Ehlken C, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol. 2011;95(3):308-17.
18. Kaiser PK, Cruess AF, Bogaert P, Khunti K, Kelly SP. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol. 2012;250(11):1563-71. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC3490068/. Accessed July 13, 2015.
19. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98. Available at: http://www.ncbi. nlm.nih.gov/pmc/articles/PMC3389193//. Accessed July 13, 2015.
20. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355(14):1409-12. Available at: http://www.nejm.org/doi/full/10.1056/NEJMp068185. Accessed July 13, 2015.